BioSpace News Archive

NeoImmuneTech, Inc., a T cell-focused immunotherapeutics company, today announced the appointment of Gene Namgoong as Chief Operating Officer (COO).

NYX-458 is currently under evaluation in a Phase 2 study in patients with mild cognitive impairment associated with Parkinson’s disease

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Dr. Julio Rosenstock to its Scientific Advisory Board.

Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for APR-246 in combination with azacitidine for the treatment of myelodysplastic syndromes (MDS) with a susceptible TP53 mutation.

Profusa, a digital health company that is pioneering the next generation of personalized medicine, today announced research findings that suggest the company’s Lumee® Oxygen Platform may help improve the clinical management of patients with critical limb ischemia (CLI) who are undergoing endovascular revascularization treatment (EVT).

BIONIK Laboratories Corp. (OTCQB:BNKL) (“BIONIK”), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced it has received regulatory approval in South Korea, and that its exclusive distributor Curexo secured the first sale for BIONIK’s InMotion® robotic technology in the country, out of Curexo’s existing inventory.

Hitachi Chemical Advanced Therapeutics Solutions, LLC (“HCATS”), a subsidiary of Hitachi Chemical Co., Ltd. representing Hitachi Chemical’s Regenerative Medicine Business Sector (“RMBS”) in North America, today announced the opening of its new cell and gene therapy manufacturing facility in Allendale, New Jersey.

Diverse Biotech, Inc. www.diversebiotech.com has announced it has been selected to present at the following prestigious events.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, announced that it was notified by the Nasdaq Office of General Counsel that the Company regained compliance with the minimum bid price rule in Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of the Company’s common stock being $1.00 per share or greater for 10 consecutive business days.

Hollister Incorporated, an independent, employee-owned company that develops, manufactures, and markets healthcare products worldwide, has been awarded a contract position on both the Premier National and Premier ASCEND agreements for ostomy products.